| Identification | Back Directory | [Name]
BMS-192364 | [CAS]
202822-21-7 | [Synonyms]
BMS-192364 UNII-1NC8D8P7QF 3H-1,2,4-Triazol-3-one, 2-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-5-[4-(trifluoromethyl)phenyl]- | [Molecular Formula]
C15H9ClF3N3O2 | [MOL File]
202822-21-7.mol | [Molecular Weight]
355.7 |
| Hazard Information | Back Directory | [Uses]
BMS-192364 is targeting the Gα-RGS interaction to produce an inactive Gα-RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux[1][2][3]. | [References]
[1] Kevin Fitzgerald, et al. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2006 Apr;2(4):e57. DOI:10.1371/journal.pgen.0020057 [2] Maciej Salaga, et al. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays. 2016 Apr;38(4):344-54. DOI:10.1002/bies.201500118 [3] David P Basile, et al. A GAP in our knowledge of vascular signaling in acute kidney injury. Kidney Int. 2011 Aug;80(3):233-5. DOI:10.1038/ki.2011.145 |
|
|